The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective.

Shaftel SS, Griffin WS, O'Banion MK. · 2008

Read The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. by Shaftel SS, Griffin WS, O'Banion MK. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2335091.txt.

Introduction

Shaftel, Griffin, and O'Banion re-examined interleukin-1 in brain disease in 2008. Interleukin-1 is a signal protein that promotes inflammation. It rises in the brain after injury and in long-term diseases such as Alzheimer's disease, the most common cause of dementia.

For two decades, most work cast this rise as harmful, driving damage and drawing white blood cells into the brain. The authors summed up newer animal studies that challenge that view. In Alzheimer models, some effects of interleukin-1 looked helpful, not harmful. They argued the protein may support repair as well as worsen injury, depending on context. Boosting its helpful side, they suggested, might ease the disease burden rather than blocking the signal outright.

Catalog record

CREATORShaftel SS, Griffin WS, O'Banion MK.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE70 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2335091

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective By Solomon S Shaftel, W Sue T Griffin, M Kerry O'Banion Published in: Journal of Neuroinflammation DOI: 10.1186/1742-2094-5-7 ABSTRACT Abstract Elevation of the proinflammatory cytokine Interleukin-1 (IL-1) is an integral part of the local tissue reaction to central nervous system (CNS) insult. The discovery of increased IL-1 levels in patients following acute injury and in chronic neurodegenerative disease laid the foundation for two decades of research that has provided important details regarding IL-1's biology and function in the CNS. IL-1 elevation is now recognized as a critical component of the brain's patterned response to insults, termed neuroinflammation, and of leukocyte recruitment to the CNS. These processes are believed to underlie IL-1's function in the setting of acute brain injury, where it has been ascribed potential roles in repair as well as in exacerbation of damage. Explorations of IL-1's role in chronic neurodegenerative disease have mainly focused on Alzheimer disease (AD), where indirect evidence has implicated it in disease pathogenesis. However, recent observations in animal models challenge earlier assumptions that IL-1 elevation and resulting neuroinflammatory processes play a purely detrimental role in AD, and prompt a need for new characterizations of IL-1 function. Potentially adaptive functions of IL-1 elevation in AD warrant further mechanistic studies, and provide evidence that enhancement of these effects may help to alleviate the pathologic burden of disease. INTRODUCTION Interleukin-1 (IL-1) comprises a pleiotropic cytokine family capable of numerous actions in the central nervous system (CNS). IL-1 classically refers to a 17 kilodalton (kDa) polypeptide existing in two distinct isoforms, IL-1α and IL-1β, although other members of the IL-1 family have recently been proposed [1]. Although IL-1α and IL-1β are encoded by separate genes sharing some sequence homology, they elicit similar biological actions. In addition to these two IL-1 receptor agonists, a native IL-1 receptor antagonist (IL-1ra) also maps to the IL-1 gene cluster on human chromosome two. All three proteins are produced as precursors, of which pro-IL-1α and pro-IL-1ra possess biological activity. Pro-IL-1β, however, requires cleavage by caspase-1 (IL-1β converting enzyme, ICE) to become biologically active. Details about the structure and regulation of these family members, as well as information about many of their actions can be found in recent reviews [2-4]. All known actions of IL-1 are mediated by a single biologically active 80 kDa cell surface receptor, the type I IL-1 receptor (IL-1RI) [5]. IL-1R1 is expressed throughout the rodent brain, with levels generally highest in neuronal rich areas including the dentate gyrus, the pyramidal cell layer of the hippocampus, and the hypothalamus [6,7]. Binding of IL-1 agonists to IL-1R1 requires association with an accessory protein to elicit downstream signal transduction that includes activation of nuclear factor-kappa B (NFκB) and mitogen-activated protein (MAP) kinase pathways [8,9]. While all known biological functions of IL-1 are attributable to IL-1 interactions with IL-1R1, some studies suggest that alternate functional IL-1 receptors may exist in the CNS [10,11]. The evolutionary importance of IL-1 activity within the brain is highlighted by the presence of two distinct endogenous regulatory pathways. IL-1ra is a competitive antagonist of IL-1R1 that selectively binds, but fails to trigger receptor association with the accessory protein resulting in blockade of all known actions of IL-1. A second 68 kDa receptor, the type II IL-1 receptor (IL-1RII), may serve as a decoy as it binds all IL-1 ligands but lacks an intracellular domain and has no demonstrated signaling function [12]. Further description of the IL-1 regulatory pathways can be found in two recent comprehensive reviews [1,13]. IL-1 actions within the CNS IL-1 was the first cytokine identified with actions on the brain [14,15]. Its ability to elicit fever after peripheral administration led to early descriptions of IL-1 as the "endogenous pyrogen". The research that followed has implicated IL-1 in a diverse array of physiologic and pathologic processes within the mammalian CNS, and has earned IL-1 status as a prototypic pro-inflammatory cytokine [13,16,17]. Generally speaking, the actions of IL-1 in the CNS are attributed to either responses of the neuroendocrine system or the local tissue microenvironment. In response to homeostatic threats in mammals, increased IL-1 levels activate the hypothalamo-pituitary-adrenal (HPA) axis and are central to elicitation of sickness behaviors. The downstream effects of this neuroendocrine system stimulation likely underlie the ability of IL-1 to modulate processes such as appetite, body temperature, epilepsy, and sleep/wake cycles in mammals [16,18-20]. This review will focus on IL-1 as a key regulator of local tissue responses to injury and disease in the CNS, with emphasis on its role in neuroinflammation. Expression of IL-1 in injury and disease Initial evidence that IL-1 may play a key role in local brain tissue reactions came from demonstrations of elevated IL-1 expression in a diverse array of CNS diseases. In humans, IL-1 is elevated in brain tissue and cerebrospinal fluid (CSF) from patients who succumbed to brain injury or stroke [21]. This pattern of expression was further extended to animal models of CNS injury where parenchymal IL-1 mRNA and protein levels are elevated in experimental models of ischemia, excitotoxicity, infection and traumatic brain injury in rodents. While IL-1α and IL-1β are barely detectable in either normal human or rodent brain, they are rapidly induced within minutes of acute experimental injuries [reviewed in [1,3,22]]. In addition to initial demonstrations of IL-1 elevations following acute injuries, similar observations have been made in a number of chronic neurodegenerative disorders. IL-1 elevations have been reported within brain lesions from patients with Alzheimer's disease (AD), Multiple Sclerosis (MS), Down's Syndrome and HIV-associated dementia [17,23-25]. Furthermore, increased IL-1 has been detected in CSF samples in MS, Parkinson's and Creutzfeldt-Jakob disease (CJD) [26-28]. These findings have since been reproduced in corresponding animal models of disease for AD, MS and CJD [29-33]. Sources and targets of IL-1 expression IL-1 is both expressed by and targeted to many different cell types within the CNS. Microglia express ICE, and in response to injury are thought to produce both the initial burst and highest levels of IL-1 production [34]. IL-1 can also be produced by astrocytes, endothelial cells, infiltrating leukocytes, neurons and oligodendrocytes [4,35,36]. In turn, IL-1 can feed back on its original cellular sources but is thought to exert its primary actions on microglia, astrocytes and endothelial cells [2]. Neuroglia and endothelial cells produce a myriad of signaling molecules in response to IL-1 stimulation. These include pro-inflammatory cytokines, chemokines, adhesion molecules, prostaglandins, reactive oxygen species, nitric oxide, and matrix metalloproteases. Notably, IL-1 induces expression of the pro-inflammatory cytokines tumor necrosis factor alpha (TNF-α) and Interleukin-6 (IL-6) as well as the enzyme cyclooxygenase-2 (COX-2) in both astrocytes and microglia in culture [4,37,38]. These inflammatory mediators have been implicated in the propagation of a number of CNS injuries and diseases [39]. IL-1β and neuroinflammation Neuroinflammation is traditionally defined as the brain's innate immune response to injury. The hallmarks of a neuroinflammatory response are phenotypic glial activation and de novo production of immune signaling molecules. Both astrocytes and microglia undergo cellular hypertrophy with increased expression of cell-surface immune modulatory proteins, including those of the major histocompatibility complex (MHC). These changes are accompanied by increased synthesis and release of pro-inflammatory cytokines and chemokines. IL-1β is intimately involved in

Read the complete text